Liposarcoma — Trials · CancerIndex

Clinical trials

Registered studies

136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 50
Recruiting: 25
Ph III recruiting: 2
Growth YoY: —
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07686367	Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers	not yet recruiting	Phase 2	42	National Cancer Institute (NCI)NIH	0	Sep 25, 2026	clinicaltrials
NCT07802652	Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma(IMMUSARC-7012)	not yet recruiting	Phase 2	80	Gustave Roussy, Cancer Campus, Grand ParisOTHER	1	Sep 15, 2026